{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:05:48Z","timestamp":1792595148103,"version":"4.5.0"},"reference-count":146,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T00:00:00Z","timestamp":1742774400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.neurot.2025.e00583","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T11:16:54Z","timestamp":1746789414000},"page":"e00583","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Repair mechanisms of the central nervous system: From axon sprouting to remyelination"],"prefix":"10.1016","volume":"22","author":[{"given":"Lauren","family":"Gluck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany","family":"Gerstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike W.","family":"Kaunzner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.neurot.2025.e00583_bib1","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1007\/s40265-013-0146-8","article-title":"Promoting remyelination in multiple sclerosis-recent advances","volume":"73","author":"M\u00fcnzel","year":"2013","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00583_bib2","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1152\/physrev.00031.2018","article-title":"Myelin in the central nervous system: structure, function, and pathology","volume":"99","author":"Stadelmann","year":"2019","journal-title":"Physiol Rev"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00583_bib3","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.4103\/1673-5374.308077","article-title":"Axonal regeneration and sprouting as a potential therapeutic target for nervous system disorders","volume":"16","author":"Marshall","year":"2021","journal-title":"Neural Regen Res"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00583_bib4","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41421-020-00233-2","article-title":"Plasma membrane integrity in health and disease: significance and therapeutic potential","volume":"7","author":"Dias","year":"2021","journal-title":"Cell Discov"},{"key":"10.1016\/j.neurot.2025.e00583_bib92","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3389\/fnins.2017.00043","article-title":"Lactate shuttles in neuroenergetics-homeostasis, allostasis and beyond","volume":"11","author":"Mason","year":"2017","journal-title":"Front Neurosci"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00583_bib5","article-title":"Human mesenchymal stem cells - current trends and future prospective","volume":"35","author":"Ullah","year":"2015","journal-title":"Biosci Rep [Internet]"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00583_bib6","article-title":"Mesenchymal stem cells for regenerative medicine","volume":"8","author":"Han","year":"2019","journal-title":"Cells [Internet]"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00583_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13578-020-00475-3","article-title":"Treatment of spinal cord injury with mesenchymal stem cells","volume":"10","author":"Liau","year":"2020","journal-title":"Cell Biosci"},{"issue":"11","key":"10.1016\/j.neurot.2025.e00583_bib127","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/nrneurol.2012.179","article-title":"Neuroplasticity and functional recovery in multiple sclerosis","volume":"8","author":"Tomassini","year":"2012","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00583_bib132","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12984-023-01272-y","article-title":"Boosting brain-computer interfaces with functional electrical stimulation: potential applications in people with locked-in syndrome","volume":"20","author":"Canny","year":"2023","journal-title":"J NeuroEng Rehabil"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00583_bib133","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1055\/s-0041-1725137","article-title":"Brain-Computer interfaces in neurorecovery and neurorehabilitation","volume":"41","author":"Young","year":"2021","journal-title":"Semin Neurol"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00583_bib8","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.neuron.2013.01.006","article-title":"Oligodendrocyte dynamics in the healthy adult CNS: evidence for myelin remodeling","volume":"77","author":"Young","year":"2013","journal-title":"Neuron"},{"issue":"7","key":"10.1016\/j.neurot.2025.e00583_bib9","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1523\/JNEUROSCI.22-07-02451.2002","article-title":"The age-related decrease in CNS remyelination efficiency is attributable to an impairment of both oligodendrocyte progenitor recruitment and differentiation","volume":"22","author":"Sim","year":"2002","journal-title":"J Neurosci"},{"issue":"Pt 12","key":"10.1016\/j.neurot.2025.e00583_bib10","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1093\/brain\/awl217","article-title":"Remyelination is extensive in a subset of multiple sclerosis patients","volume":"129","author":"Patrikios","year":"2006","journal-title":"Brain"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00583_bib11","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1093\/brain\/awq250","article-title":"Demyelination versus remyelination in progressive multiple sclerosis","volume":"133","author":"Bramow","year":"2010","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00583_bib12","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1038\/s41467-019-11638-3","article-title":"Oligodendrocyte precursor cells present antigen and are cytotoxic targets in inflammatory demyelination","volume":"10","author":"Kirby","year":"2019","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00583_bib13","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/nn.4193","article-title":"Oligodendrocyte death results in immune-mediated CNS demyelination","volume":"19","author":"Traka","year":"2016","journal-title":"Nat Neurosci"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00583_bib14","article-title":"From OPC to oligodendrocyte: an epigenetic journey","volume":"8","author":"Tiane","year":"2019","journal-title":"Cells [Internet]"},{"issue":"3-4","key":"10.1016\/j.neurot.2025.e00583_bib15","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1101\/gad.344218.120","article-title":"Cell of all trades: oligodendrocyte precursor cells in synaptic, vascular, and immune function","volume":"35","author":"Akay","year":"2021","journal-title":"Genes Dev"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00583_bib16","doi-asserted-by":"crossref","first-page":"8570","DOI":"10.1038\/s41467-024-52444-w","article-title":"CRISPR-edited human ES-derived oligodendrocyte progenitor cells improve remyelination in rodents","volume":"15","author":"Wagstaff","year":"2024","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00583_bib17","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s00401-013-1112-y","article-title":"Insufficient OPC migration into demyelinated lesions is a cause of poor remyelination in MS and mouse models","volume":"125","author":"Boyd","year":"2013","journal-title":"Acta Neuropathol"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00583_bib18","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.ajpath.2015.11.005","article-title":"Pre-existing mature oligodendrocytes do not contribute to remyelination following toxin-induced spinal cord demyelination","volume":"186","author":"Crawford","year":"2016","journal-title":"Am J Pathol"},{"issue":"50","key":"10.1016\/j.neurot.2025.e00583_bib19","doi-asserted-by":"crossref","first-page":"E11807","DOI":"10.1073\/pnas.1808064115","article-title":"The adult oligodendrocyte can participate in remyelination","volume":"115","author":"Duncan","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00583_bib20","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41593-021-01009-x","article-title":"New oligodendrocytes exhibit more abundant and accurate myelin regeneration than those that survive demyelination","volume":"25","author":"Neely","year":"2022","journal-title":"Nat Neurosci"},{"issue":"11","key":"10.1016\/j.neurot.2025.e00583_bib21","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1016\/j.neuron.2023.03.031","article-title":"Remyelination by surviving oligodendrocytes is inefficient in the inflamed mammalian cortex","volume":"111","author":"Mezydlo","year":"2023","journal-title":"Neuron"},{"issue":"26","key":"10.1016\/j.neurot.2025.e00583_bib22","doi-asserted-by":"crossref","first-page":"22184","DOI":"10.1074\/jbc.M112.366179","article-title":"LINGO-1, a transmembrane signaling protein, inhibits oligodendrocyte differentiation and myelination through intercellular self-interactions","volume":"287","author":"Jepson","year":"2012","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00583_bib23","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S1474-4422(16)30377-5","article-title":"Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial","volume":"16","author":"Cadavid","year":"2017","journal-title":"Lancet Neurol"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00583_bib24","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S1474-4422(19)30137-1","article-title":"Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial","volume":"18","author":"Cadavid","year":"2019","journal-title":"Lancet Neurol"},{"issue":"10111","key":"10.1016\/j.neurot.2025.e00583_bib25","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1016\/S0140-6736(17)32346-2","article-title":"Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial","volume":"390","author":"Green","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.neurot.2025.e00583_bib26","first-page":"1","article-title":"Clemastine fumarate accelerates accumulation of disability in progressive multiple sclerosis by enhancing pyroptosis [Internet]","author":"Kocot","year":"2024","journal-title":"medRxiv"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00583_bib27","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nn.2702","article-title":"Retinoid X receptor gamma signaling accelerates CNS remyelination","volume":"14","author":"Huang","year":"2011","journal-title":"Nat Neurosci"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00583_bib28","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S1474-4422(21)00179-4","article-title":"Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study","volume":"20","author":"Brown","year":"2021","journal-title":"Lancet Neurol"},{"issue":"21","key":"10.1016\/j.neurot.2025.e00583_bib29","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1016\/j.neuron.2022.09.023","article-title":"CNS remyelination and inflammation: from basic mechanisms to therapeutic opportunities","volume":"110","author":"Franklin","year":"2022","journal-title":"Neuron"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00583_bib30","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.stem.2019.08.015","article-title":"Metformin restores CNS remyelination capacity by rejuvenating aged stem cells","volume":"25","author":"Neumann","year":"2019","journal-title":"Cell Stem Cell"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00583_bib31","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1001\/jamaneurol.2015.4807","article-title":"Immunologic effects of metformin and pioglitazone treatment on metabolic syndrome and multiple sclerosis","volume":"73","author":"Negrotto","year":"2016","journal-title":"JAMA Neurol"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00583_bib32","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1002\/acn3.260","article-title":"Pioglitazone regulates myelin phagocytosis and multiple sclerosis monocytes","volume":"2","author":"Natrajan","year":"2015","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.neurot.2025.e00583_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1362629","article-title":"A metformin add-on clinical study in multiple sclerosis to evaluate brain remyelination and neurodegeneration (MACSiMiSE-BRAIN): study protocol for a multi-center randomized placebo controlled clinical trial","volume":"15","author":"De Keersmaecker","year":"2024","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00583_bib34","doi-asserted-by":"crossref","first-page":"e380","DOI":"10.1212\/NXI.0000000000000380","article-title":"Lipoic acid pharmacokinetics at baseline and 1 year in secondary progressive MS","volume":"4","author":"Bittner","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1-2","key":"10.1016\/j.neurot.2025.e00583_bib35","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jneuroim.2009.04.011","article-title":"A pilot test of pioglitazone as an add-on in patients with relapsing remitting multiple sclerosis","volume":"211","author":"Kaiser","year":"2009","journal-title":"J Neuroimmunol"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00583_bib36","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1742-2094-1-3","article-title":"Effect of pioglitazone treatment in a patient with secondary multiple sclerosis","volume":"1","author":"Pershadsingh","year":"2004","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.neurot.2025.e00583_bib145","unstructured":"Chataway J, et al. The optimal clinical trials platform for progressive multiple sclerosis (OCTOPUS) trial: an update. Presented at: ECTRIMS congress; september 18-20, 2024; Copenhagen, Denmark. ABSTRACT 1632\/913."},{"key":"10.1016\/j.neurot.2025.e00583_bib117","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.psyneuen.2015.09.023","article-title":"Short-term calorie restriction enhances adult hippocampal neurogenesis and remote fear memory in a Ghsr-dependent manner","volume":"63","author":"Hornsby","year":"2016","journal-title":"Psychoneuroendocrinology"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00583_bib118","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1073\/pnas.0808587106","article-title":"Caloric restriction improves memory in elderly humans","volume":"106","author":"Witte","year":"2009","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"3","key":"10.1016\/j.neurot.2025.e00583_bib119","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-020-2406-3","article-title":"Caloric restriction triggers morphofunctional remodeling of astrocytes and enhances synaptic plasticity in the mouse hippocampus","volume":"11","author":"Popov","year":"2020","journal-title":"Cell Death Dis"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00583_bib120","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.cmet.2012.04.003","article-title":"SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function","volume":"15","author":"Price","year":"2012","journal-title":"Cell Metab"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00583_bib121","doi-asserted-by":"crossref","first-page":"E751","DOI":"10.1152\/ajpendo.00745.2009","article-title":"AMPK and SIRT1: a long-standing partnership?","volume":"298","author":"Ruderman","year":"2010","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00583_bib122","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.molcel.2010.09.023","article-title":"Autophagy and the integrated stress response","volume":"40","author":"Kroemer","year":"2010","journal-title":"Mol Cell"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00583_bib123","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/s43587-021-00098-4","article-title":"Autophagy in healthy aging and disease","volume":"1","author":"Aman","year":"2021","journal-title":"Nature Aging"},{"key":"10.1016\/j.neurot.2025.e00583_bib124","article-title":"Exercise promotes the expression of brain derived neurotrophic factor (BDNF) through the action of the ketone body \u03b2-hydroxybutyrate","volume":"5","author":"Sleiman","year":"2016","journal-title":"Elife [Internet]"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00583_bib37","article-title":"Antioxidant therapies in the treatment of multiple sclerosis","volume":"14","author":"Jim\u00e9nez-Jim\u00e9nez","year":"2024","journal-title":"Biomolecules [Internet]"},{"issue":"7","key":"10.1016\/j.neurot.2025.e00583_bib38","article-title":"A review of various antioxidant compounds and their potential utility as complementary therapy in multiple sclerosis","volume":"11","author":"Miller","year":"2019","journal-title":"Nutrients [Internet]"},{"key":"10.1016\/j.neurot.2025.e00583_bib39","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s42255-018-0014-7","article-title":"Coupling Krebs cycle metabolites to signalling in immunity and cancer","volume":"1","author":"Ryan","year":"2019","journal-title":"Nat Metab"},{"key":"10.1016\/j.neurot.2025.e00583_bib40","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3389\/fimmu.2018.00141","article-title":"A role for the krebs cycle intermediate citrate in metabolic reprogramming in innate immunity and inflammation","volume":"9","author":"Williams","year":"2018","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.neurot.2025.e00583_bib41","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1007\/s00429-018-1680-7","article-title":"Protective potential of dimethyl fumarate in a mouse model of thalamocortical demyelination","volume":"223","author":"Cerina","year":"2018","journal-title":"Brain Struct Funct"},{"issue":"7","key":"10.1016\/j.neurot.2025.e00583_bib42","article-title":"Mechanisms of demyelination and remyelination strategies for multiple sclerosis","volume":"24","author":"Zhao","year":"2023","journal-title":"Int J Mol Sci [Internet]"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00583_bib43","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1177\/1352458516661048","article-title":"High-dose erythropoietin in patients with progressive multiple sclerosis: a randomized, placebo-controlled, phase 2 trial","volume":"23","author":"Schreiber","year":"2017","journal-title":"Mult Scler"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00583_bib44","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11011-017-0099-9","article-title":"Alpha-lipoic acid mitigates toxic-induced demyelination in the corpus callosum by lessening of oxidative stress and stimulation of polydendrocytes proliferation","volume":"33","author":"Sanadgol","year":"2018","journal-title":"Metab Brain Dis"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00583_bib45","doi-asserted-by":"crossref","first-page":"e374","DOI":"10.1212\/NXI.0000000000000374","article-title":"Lipoic acid in secondary progressive MS: a randomized controlled pilot trial","volume":"4","author":"Spain","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00583_bib46","article-title":"A double-blind, placebo-controlled, single-ascending-dose intravenous infusion study of rHIgM22 in subjects with multiple sclerosis immediately following a relapse","volume":"8","author":"Greenberg","year":"2022","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00583_bib47","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202114759","article-title":"Genetically modified macrophages accelerate myelin repair","volume":"14","author":"Aigrot","year":"2022","journal-title":"EMBO Mol Med"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00583_bib48","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/jnr.25129","article-title":"Cell-based experimental strategies for myelin repair in multiple sclerosis","volume":"101","author":"Borda","year":"2023","journal-title":"J Neurosci Res"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00583_bib49","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00401-020-02193-z","article-title":"TREM2 activation on microglia promotes myelin debris clearance and remyelination in a model of multiple sclerosis","volume":"140","author":"Cignarella","year":"2020","journal-title":"Acta Neuropathol"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00583_bib50","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s00401-020-02129-7","article-title":"Niacin-mediated rejuvenation of macrophage\/microglia enhances remyelination of the aging central nervous system","volume":"139","author":"Rawji","year":"2020","journal-title":"Acta Neuropathol"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00583_bib51","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1242\/dev.106492","article-title":"Combinatorial actions of Tgf\u03b2 and Activin ligands promote oligodendrocyte development and CNS myelination","volume":"141","author":"Dutta","year":"2014","journal-title":"Development"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00583_bib146","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.cmet.2019.09.010","article-title":"Roles of regulatory T cells in tissue pathophysiology and metabolism","volume":"31","author":"Campbell","year":"2020","journal-title":"Cell Metab"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00583_bib147","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1007\/s13311-011-0065-x","article-title":"Myelin regeneration in multiple sclerosis: targeting endogenous stem cells","volume":"8","author":"Huang","year":"2011","journal-title":"Neurotherapeutics"},{"issue":"32","key":"10.1016\/j.neurot.2025.e00583_bib53","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2407974121","article-title":"Targeting the muscarinic M1 receptor with a selective, brain-penetrant antagonist to promote remyelination in multiple sclerosis","volume":"121","author":"Poon","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"44","key":"10.1016\/j.neurot.2025.e00583_bib54","article-title":"Targeting the muscarinic M1 receptor with a selective, brain-penetrant antagonist to promote remyelination in multiple sclerosis","volume":"121","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00583_bib55","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1007\/s00330-009-1364-z","article-title":"MR spectroscopy (MRS) and magnetisation transfer imaging (MTI), lesion load and clinical scores in early relapsing remitting multiple sclerosis: a combined cross-sectional and longitudinal study","volume":"19","author":"Bellmann-Strobl","year":"2009","journal-title":"Eur Radiol"},{"key":"10.1016\/j.neurot.2025.e00583_bib56","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.nicl.2015.09.003","article-title":"Measuring longitudinal myelin water fraction in new multiple sclerosis lesions","volume":"9","author":"Vargas","year":"2015","journal-title":"Neuroimage Clin"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00583_bib57","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/jon.12716","article-title":"Impact of lesion location on longitudinal myelin water fraction change in chronic multiple sclerosis lesions","volume":"30","author":"Pandya","year":"2020","journal-title":"J Neuroimaging"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00583_bib58","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/jon.12082","article-title":"Identifying the start of multiple sclerosis injury: a serial DTI study","volume":"24","author":"Ontaneda","year":"2014","journal-title":"J Neuroimaging"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00583_bib59","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/197140091302600101","article-title":"Diffusion tensor magnetic resonance imaging in patients with multiple sclerosis and its relationship with disability","volume":"26","author":"Temel","year":"2013","journal-title":"NeuroRadiol J"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00583_bib60","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/ana.22521","article-title":"Multiple sclerosis normal-appearing white matter: pathology-imaging correlations","volume":"70","author":"Moll","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurot.2025.e00583_bib61","series-title":"Basic neurochemistry: molecular, cellular and medical aspects","article-title":"Axon sprouting and reactive synaptogenesis","author":"Cotman","year":"1999"},{"key":"10.1016\/j.neurot.2025.e00583_bib62","doi-asserted-by":"crossref","first-page":"486","DOI":"10.3389\/fphys.2019.00486","article-title":"Effects of neurotrophic factors in glial cells in the central nervous system: expression and properties in neurodegeneration and injury","volume":"10","author":"P\u00f6yh\u00f6nen","year":"2019","journal-title":"Front Physiol"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00583_bib63","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1006\/exnr.1997.6705","article-title":"Neurotrophic factors increase axonal growth after spinal cord injury and transplantation in the adult rat","volume":"148","author":"Bregman","year":"1997","journal-title":"Exp Neurol"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00583_bib64","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1084\/jem.20041918","article-title":"Inhibition of astroglial nuclear factor kappaB reduces inflammation and improves functional recovery after spinal cord injury","volume":"202","author":"Brambilla","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.neurot.2025.e00583_bib65","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2022.955598","article-title":"Capacity of astrocytes to promote axon growth in the injured mammalian central nervous system","volume":"16","author":"Hemati-Gourabi","year":"2022","journal-title":"Front Neurosci"},{"key":"10.1016\/j.neurot.2025.e00583_bib66","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.brainres.2014.08.064","article-title":"Molecular mechanisms of scar-sourced axon growth inhibitors","volume":"1619","author":"Ohtake","year":"2015","journal-title":"Brain Res"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00583_bib67","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.expneurol.2011.05.001","article-title":"Role of myelin-associated inhibitors in axonal repair after spinal cord injury","volume":"235","author":"Lee","year":"2012","journal-title":"Exp Neurol"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00583_bib68","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.expneurol.2011.06.006","article-title":"Myelin associated inhibitors: a link between injury-induced and experience-dependent plasticity","volume":"235","author":"Akbik","year":"2012","journal-title":"Exp Neurol"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00583_bib69","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.4103\/1673-5374.213538","article-title":"LINGO-1 and AMIGO3, potential therapeutic targets for neurological and dysmyelinating disorders?","volume":"12","author":"Foale","year":"2017","journal-title":"Neural Regen Res"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00583_bib70","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/nn1188","article-title":"LINGO-1 is a component of the Nogo-66 receptor\/p75 signaling complex","volume":"7","author":"Mi","year":"2004","journal-title":"Nat Neurosci"},{"issue":"15","key":"10.1016\/j.neurot.2025.e00583_bib71","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1523\/JNEUROSCI.4353-06.2007","article-title":"Nonsteroidal anti-inflammatory drugs promote axon regeneration via RhoA inhibition","volume":"27","author":"Fu","year":"2007","journal-title":"J Neurosci"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00583_bib72","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1177\/2192568220901689","article-title":"Nonsteroidal anti-inflammatory drugs and their neuroprotective role after an acute spinal cord injury: a systematic review of animal models","volume":"11","author":"Lambrechts","year":"2021","journal-title":"Glob Spine J"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00583_bib73","article-title":"Epothilones improve axonal growth and motor outcomes after stroke in the adult mammalian CNS","volume":"1","author":"Kugler","year":"2020","journal-title":"Cell Rep Med"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00583_bib74","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcad005","article-title":"Rehabilitation enhances epothilone-induced locomotor recovery after spinal cord injury","volume":"5","author":"Griffin","year":"2023","journal-title":"Brain Commun"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00583_bib75","doi-asserted-by":"crossref","DOI":"10.1042\/AN20130030","article-title":"PPAR agonists as therapeutics for CNS trauma and neurological diseases","volume":"5","author":"Mandrekar-Colucci","year":"2013","journal-title":"ASN Neuro"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00583_bib76","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2200057120","article-title":"Intranasal delivery of full-length anti-Nogo-A antibody: a potential alternative route for therapeutic antibodies to central nervous system targets","volume":"120","author":"Correa","year":"2023","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"3","key":"10.1016\/j.neurot.2025.e00583_bib77","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s13311-020-00864-z","article-title":"Targeting therapeutic antibodies to the CNS: a comparative study of intrathecal, intravenous, and subcutaneous anti-Nogo A antibody treatment after stroke in rats","volume":"17","author":"Wahl","year":"2020","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neurot.2025.e00583_bib78","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jconrel.2023.12.041","article-title":"Nogo-A neutralization in the central nervous system with a blood-brain barrier-penetrating antibody","volume":"366","author":"Joly","year":"2024","journal-title":"J Control Release"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00583_bib79","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1038\/nm1668","article-title":"Acid-sensing ion channel-1 contributes to axonal degeneration in autoimmune inflammation of the central nervous system","volume":"13","author":"Friese","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.neurot.2025.e00583_bib80","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/B978-0-444-52001-2.00005-4","article-title":"Axonal loss in multiple sclerosis: causes and mechanisms","volume":"122","author":"Criste","year":"2014","journal-title":"Handb Clin Neurol"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00583_bib81","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/14740338.2017.1250881","article-title":"Safety of monoclonal antibodies for the treatment of multiple sclerosis","volume":"16","author":"McGinley","year":"2017","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00583_bib82","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/j.1471-4159.2005.03238.x","article-title":"Why do Nogo\/Nogo-66 receptor gene knockouts result in inferior regeneration compared to treatment with neutralizing agents?","volume":"94","author":"Teng","year":"2005","journal-title":"J Neurochem"},{"issue":"26","key":"10.1016\/j.neurot.2025.e00583_bib83","doi-asserted-by":"crossref","first-page":"8685","DOI":"10.1523\/JNEUROSCI.3817-13.2014","article-title":"Neutralization of Nogo-A enhances synaptic plasticity in the rodent motor cortex and improves motor learning in vivo","volume":"34","author":"Zemmar","year":"2014","journal-title":"J Neurosci"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00583_bib84","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0061878","article-title":"AMIGO3 is an NgR1\/p75 co-receptor signalling axon growth inhibition in the acute phase of adult central nervous system injury","volume":"8","author":"Ahmed","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00583_bib85","doi-asserted-by":"crossref","first-page":"4126","DOI":"10.1038\/s41467-018-06505-6","article-title":"Modulation of proteoglycan receptor PTP\u03c3 enhances MMP-2 activity to promote recovery from multiple sclerosis","volume":"9","author":"Luo","year":"2018","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00583_bib86","article-title":"Efficacy and safety of masitinib in progressive forms of multiple sclerosis: a randomized, phase 3, clinical trial","volume":"9","author":"Vermersch","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm [Internet]"},{"key":"10.1016\/j.neurot.2025.e00583_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.wnsx.2023.100201","article-title":"Stem cell-derived extracellular vesicle-based therapy for nerve injury: a review of the molecular mechanisms","volume":"19","author":"Nasiry","year":"2023","journal-title":"World Neurosurg X"},{"key":"10.1016\/j.neurot.2025.e00583_bib88","doi-asserted-by":"crossref","first-page":"736","DOI":"10.3389\/fcell.2020.00736","article-title":"Functional electrical stimulation and the modulation of the axon regeneration program","volume":"8","author":"Jara","year":"2020","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00583_bib139","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ncl.2017.08.002","article-title":"Multiple sclerosis: mechanisms of disease and strategies for myelin and axonal repair","volume":"36","author":"Lemus","year":"2018","journal-title":"Neurol Clin"},{"issue":"1-2","key":"10.1016\/j.neurot.2025.e00583_bib89","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3109\/00207459908994307","article-title":"Serotonergic neuronal sprouting as a potential mechanism of recovery in multiple sclerosis","volume":"97","author":"Sandyk","year":"1999","journal-title":"Int J Neurosci"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00583_bib90","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.20040452","article-title":"Remodeling of axonal connections contributes to recovery in an animal model of multiple sclerosis","volume":"200","author":"Kerschensteiner","year":"2004","journal-title":"J Exp Med"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00583_bib91","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrn.2018.19","article-title":"Lactate in the brain: from metabolic end-product to signalling molecule","volume":"19","author":"Magistretti","year":"2018","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.neurot.2025.e00583_bib93","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.expneurol.2018.07.009","article-title":"Glia-neuron energy metabolism in health and diseases: new insights into the role of nervous system metabolic transporters","volume":"309","author":"Jha","year":"2018","journal-title":"Exp Neurol"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00583_bib94","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/glia.1119","article-title":"Oligodendrocytes use lactate as a source of energy and as a precursor of lipids","volume":"36","author":"S\u00e1nchez-Abarca","year":"2001","journal-title":"Glia"},{"issue":"2023","key":"10.1016\/j.neurot.2025.e00583_bib95","article-title":"Mitophagy and traumatic brain injury: regulatory mechanisms and therapeutic potentials","volume":"17","author":"Luan","year":"2023","journal-title":"Oxid Med Cell Longev"},{"issue":"14","key":"10.1016\/j.neurot.2025.e00583_bib96","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1016\/j.cub.2021.04.079","article-title":"Reprogramming an energetic AKT-PAK5 axis boosts axon energy supply and facilitates neuron survival and regeneration after injury and ischemia","volume":"31","author":"Huang","year":"2021","journal-title":"Curr Biol"},{"key":"10.1016\/j.neurot.2025.e00583_bib97","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102036","article-title":"Efficacy and safety of CNM-Au8 in amyotrophic lateral sclerosis (RESCUE-ALS study): a phase 2, randomised, double-blind, placebo-controlled trial and open label extension","volume":"60","author":"Vucic","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00583_bib98","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1186\/s12951-023-02236-z","article-title":"Evidence of brain target engagement in Parkinson's disease and multiple sclerosis by the investigational nanomedicine, CNM-Au8, in the REPAIR phase 2 clinical trials","volume":"21","author":"Ren","year":"2023","journal-title":"J Nanobiotechnol"},{"key":"10.1016\/j.neurot.2025.e00583_bib99","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/1742-2094-10-106","article-title":"Anti-inflammatory and immunomodulatory mechanisms of mesenchymal stem cell transplantation in experimental traumatic brain injury","volume":"10","author":"Zhang","year":"2013","journal-title":"J Neuroinflamm"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00583_bib100","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.tips.2020.06.009","article-title":"Mesenchymal stem cell immunomodulation: mechanisms and therapeutic potential","volume":"41","author":"Song","year":"2020","journal-title":"Trends Pharmacol Sci"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00583_bib101","article-title":"Utilising induced pluripotent stem cells in neurodegenerative disease research: focus on glia","volume":"22","author":"Albert","year":"2021","journal-title":"Int J Mol Sci [Internet]"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00583_bib102","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-024-01809-0","article-title":"Induced pluripotent stem cells (iPSCs): molecular mechanisms of induction and applications","volume":"9","author":"Cerneckis","year":"2024","journal-title":"Signal Transduct Targeted Ther"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00583_bib103","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2017.504","article-title":"Current progress in the derivation and therapeutic application of neural stem cells","volume":"8","author":"Tang","year":"2017","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.neurot.2025.e00583_bib104","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/1958631","article-title":"Employing endogenous NSCs to promote recovery of spinal cord injury","volume":"2019","author":"Liu","year":"2019","journal-title":"Stem Cells Int."},{"issue":"4","key":"10.1016\/j.neurot.2025.e00583_bib105","article-title":"Mesenchymal stem cell derived extracellular vesicles for tissue engineering and regenerative medicine applications","volume":"9","author":"Tsiapalis","year":"2020","journal-title":"Cells [Internet]"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00583_bib106","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-023-01704-0","article-title":"Clinical applications of stem cell-derived exosomes","volume":"9","author":"Tan","year":"2024","journal-title":"Signal Transduct Targeted Ther"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00583_bib107","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s13287-023-03409-1","article-title":"Neural stem cell-derived exosomes and regeneration: cell-free therapeutic strategies for traumatic brain injury","volume":"14","author":"Zhong","year":"2023","journal-title":"Stem Cell Res Ther"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00583_bib108","article-title":"Therapeutic application of exosomes in inflammatory diseases","volume":"22","author":"Suh","year":"2021","journal-title":"Int J Mol Sci [Internet]"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00583_bib109","article-title":"Exosomes: potential disease biomarkers and new therapeutic targets","volume":"9","author":"Mosquera-Heredia","year":"2021","journal-title":"Biomedicines [Internet]"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00583_bib140","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1172\/JCI95145","article-title":"Cellular senescence in brain aging and neurodegenerative diseases: evidence and perspectives","volume":"128","author":"Baker","year":"2018","journal-title":"J Clin Investig"},{"key":"10.1016\/j.neurot.2025.e00583_bib141","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111327","article-title":"Evidence and perspectives of cell senescence in neurodegenerative diseases","volume":"137","author":"Si","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.neurot.2025.e00583_bib110","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1146\/annurev-pathol-121808-102144","article-title":"The senescence-associated secretory phenotype: the dark side of tumor suppression","volume":"5","author":"Copp\u00e9","year":"2010","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.neurot.2025.e00583_bib111","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.exger.2014.09.018","article-title":"Cellular senescence and the aging brain","volume":"68","author":"Chinta","year":"2015","journal-title":"Exp Gerontol"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00583_bib142","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.neuron.2014.06.010","article-title":"Glial development: the crossroads of regeneration and repair in the CNS","volume":"83","author":"Gallo","year":"2014","journal-title":"Neuron"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00583_bib112","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/joim.13141","article-title":"Senolytic drugs: from discovery to translation","volume":"288","author":"Kirkland","year":"2020","journal-title":"J Intern Med"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00583_bib113","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1038\/s41591-022-01923-y","article-title":"Cellular senescence and senolytics: the path to the clinic","volume":"28","author":"Chaib","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.neurot.2025.e00583_bib114","doi-asserted-by":"crossref","DOI":"10.1016\/j.mad.2024.111995","article-title":"Fisetin as a senotherapeutic agent: evidence and perspectives for age-related diseases","volume":"222","author":"Tavenier","year":"2024","journal-title":"Mech Ageing Dev"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00583_bib115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-023-01343-5","article-title":"Cellular rejuvenation: molecular mechanisms and potential therapeutic interventions for diseases","volume":"8","author":"Ji","year":"2023","journal-title":"Signal Transduct Targeted Ther"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00583_bib116","doi-asserted-by":"crossref","first-page":"22","DOI":"10.14283\/jpad.2021.62","article-title":"Senolytic therapy to modulate the progression of Alzheimer's disease (SToMP-AD): a pilot clinical trial","volume":"9","author":"Gonzales","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.neurot.2025.e00583_bib125","article-title":"mTOR as a central regulator of lifespan and aging","volume":"8","author":"Papadopoli","year":"2019","journal-title":"F1000Res [Internet]"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00583_bib126","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-023-01608-z","article-title":"Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease","volume":"8","author":"Panwar","year":"2023","journal-title":"Signal Transduct Targeted Ther"},{"key":"10.1016\/j.neurot.2025.e00583_bib143","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2024.114889","article-title":"Mitophagy activation by rapamycin enhances mitochondrial function and cognition in 5\u00d7FAD mice","volume":"463","author":"Zheng","year":"2024","journal-title":"Behav Brain Res"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00583_bib144","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.bbrc.2014.01.032","article-title":"Rapamycin attenuates mitochondrial dysfunction via activation of mitophagy in experimental ischemic stroke","volume":"444","author":"Li","year":"2014","journal-title":"Biochem Biophys Res Commun"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00583_bib128","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1016\/j.celrep.2018.08.060","article-title":"Multimodal enhancement of remyelination by exercise with a pivotal role for oligodendroglial PGC1\u03b1","volume":"24","author":"Jensen","year":"2018","journal-title":"Cell Rep"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00583_bib129","doi-asserted-by":"crossref","first-page":"112","DOI":"10.5312\/wjo.v9.i9.112","article-title":"Robotic exoskeletons: the current pros and cons","volume":"9","author":"Gorgey","year":"2018","journal-title":"World J Orthop"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00583_bib130","article-title":"Exoskeletons for mobility after spinal cord injury: a personalized embodied approach","volume":"12","author":"Forte","year":"2022","journal-title":"J Pers Med [Internet]"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00583_bib131","article-title":"The effects of powered exoskeleton gait training on cardiovascular function and gait performance: a systematic review","volume":"21","author":"Duddy","year":"2021","journal-title":"Sensors (Basel) [Internet]"},{"key":"10.1016\/j.neurot.2025.e00583_bib134","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.nbd.2014.11.025","article-title":"Brain-machine interfaces in neurorehabilitation of stroke","volume":"83","author":"Soekadar","year":"2015","journal-title":"Neurobiol Dis"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00583_bib135","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1152\/physrev.00027.2016","article-title":"Brain-machine interfaces: from basic science to neuroprostheses and neurorehabilitation","volume":"97","author":"Lebedev","year":"2017","journal-title":"Physiol Rev"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00583_bib136","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.tins.2006.07.004","article-title":"Brain-machine interfaces: past, present and future","volume":"29","author":"Lebedev","year":"2006","journal-title":"Trends Neurosci"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00583_bib137","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S1474-4422(20)30347-1","article-title":"Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"19","author":"Cree","year":"2020","journal-title":"Lancet Neurol"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00583_bib138","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-086414","article-title":"Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis (MS-STAT2): protocol for a multicentre, randomised controlled, double-blind, phase 3 clinical trial in the UK","volume":"14","author":"Blackstone","year":"2024","journal-title":"BMJ Open"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747925000613?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747925000613?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T13:03:43Z","timestamp":1755090223000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747925000613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":146,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1878747925000613"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2025.e00583","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repair mechanisms of the central nervous system: From axon sprouting to remyelination","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2025.e00583","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00583"}}